

Effective Date: 01/01/2022
Reviewed: 10/2021, 9/2022, 5/2023, 6/2024, 12/2024, 6/2025
Scope: Medicaid

Kerendia (finerenone)

POLICY

I. CRITERIA FOR APPROVAL

An authorization of 12 months may be granted when all the following criteria are met:

- A. Patient is 18 years or older; AND
- B. The medication is prescribed by, or in consultation with, a cardiologist, endocrinologist, or nephrologist; AND
- C. Patient has documented diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes; AND
- D. Member meets all of the following at baseline:
 - a. Estimated glomerular filtration rate (eGFR) is ≥ 25 mL/min/1.73m²; AND
 - b. Urine albumin-to-creatinine ratio [UACR] is ≥ 30 mg/g; AND
 - c. Serum potassium level ≤ 5.0 mEq/L
- E. Documentation that patient is currently receiving a maximally tolerated and stabilized dose of an Angiotensin Converting Enzyme inhibitor (ACEi, e.g., lisinopril) or an Angiotensin Receptor Blocker (ARB, e.g., losartan), unless all agents in these classes are contraindicated; AND
- F. Documentation that patient is currently receiving a maximally tolerated dose of a sodium-glucose co-transporter 2 (SGLT2) inhibitor with renal benefit (e.g., dapagliflozin [Farxiga]) or has experienced a documented intolerance or contraindication that would prohibit a trial of a SGLT2 inhibitor with renal benefit (e.g., dapagliflozin [Farxiga])

II. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for all members when the following criteria are met:

- A. Patients meets all initial criteria; AND
- B. Patient has exhibited improvement or stability of disease symptoms (e.g., stabilization of eGFR, lack of hospitalization due to renal or cardiovascular disease); OR in the absence of improvement or stability of disease symptoms, the provider attests that continuation of therapy is medically necessary AND clinical rationale of medical necessity has been provided.

III. QUANTITY LIMIT

Kerendia 10mg or 20mg: one tablet per day

IV. COVERAGE DURATION

- 12 months

Effective Date: 01/01/2022
Reviewed: 10/2021, 9/2022, 5/2023, 6/2024, 12/2024, 6/2025
Scope: Medicaid

V. REFERENCES

1. Kerendia [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; September 2022.
2. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes – 2023. *Diabetes Care*. Dec 2022;46:S191-S202.
3. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney International*. 2022;102(Suppl 5S):S1-S127.